Phosphodiesterases: Regulators of cyclic nucleotide signals and novel molecular target for movement disorders

European Journal of Pharmacology

Volumn 714, Issue 1-3, 2013, Pages 486-497

  Sharma, Sorabh ^a   Kumar, Kushal ^a   Deshmukh, Rahul ^a   Sharma, Pyare Lal ^a  

^a ISF COLLEGE OF PHARMACY   (India)

Author keywords

Cyclic nucleotides; Dyskinesia's; Huntington's disease; Movement disorders; Parkinson's disease; Phosphodiesterase inhibitors

Indexed keywords

2 METHYL 5 NITROBENZENESULFONIC ACID DIMETHYLAMIDE; 4 (3 BUTOXY 4 METHOXYBENZYL) 2 IMIDAZOLIDINONE; BAY 60 7550; BAY 736691; BRAIN DERIVED NEUROTROPHIC FACTOR; CILOSTAZOL; CYCLIC AMP; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLIC NUCLEOTIDE; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; LEVODOPA; MK 0952; PHOSPHODIESTERASE; PHOSPHODIESTERASE I; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; PHOSPHODIESTERASE VII; PHOSPHODIESTERASE X; ROLIPRAM; S 14; SILDENAFIL; TADALAFIL; TETRABENAZINE; THPP 1; TP 10; TREQUINSIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VARDENAFIL; ZAPRINAST;

AKATHISIA; ARTICLE; BRAIN HYPOXIA; BRAIN REGION; CAROTID ARTERY OBSTRUCTION; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DEPRESSION; DISEASE ASSOCIATION; DRUG TARGETING; DYSKINESIA; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME STRUCTURE; HUMAN; HUNTINGTON CHOREA; MEMORY DISORDER; MIDDLE CEREBRAL ARTERY OCCLUSION; MOTOR DYSFUNCTION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; PARKINSON DISEASE; PARKINSONISM; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SUICIDAL BEHAVIOR; TARDIVE DYSKINESIA; UPREGULATION;

CYCLIC NUCLEOTIDES; DYSKINESIA'S; HUNTINGTON'S DISEASE; MOVEMENT DISORDERS; PARKINSON'S DISEASE; PHOSPHODIESTERASE INHIBITORS;

ANIMALS; HUMANS; MOLECULAR TARGETED THERAPY; MOVEMENT DISORDERS; NUCLEOTIDES, CYCLIC; PHOSPHORIC DIESTER HYDROLASES; SIGNAL TRANSDUCTION;

EID: 84885472234     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2013.06.038     Document Type: Review

References (201)

1. Almeida, S., Cunha-Oliveira, T., Laco, M., Oliveira, C.R., Rego, A.C., 2010. Dysregulation of CREB activation and histone acetylation in 3-nitropropionic acid-treated cortical neurons: prevention by BDNF and NGF. Neurotox. Res. 17, 399-405.
2. Barankiewicz, J., Danks, A.M., Abushanab, E., Makings, L., Wiemann, T., Wallis, R.A., Pragnacharyulu, P.V., Fox, A., Marangos, P.J., 1997. Regulation of adenosine concentration and cytoprotective effects of novel reversible adenosine deami-nase inhibitors. J. Pharmacol. Exp. Ther. 283, 1230-1238. (Pubitemid 28016498)
3. Baratti, C.M., Boccia, M.M., 1999. Effects of sildenafil on long-term retention of an inhibitory avoidance response in mice. Behav. Pharmacol. 10, 731-737. (Pubitemid 30028747)
4. Beal, M.F., Brouillet, E., Jenkins, B.G., Ferrante, R.J., Kowall, N.W., Miller, J.M., Storey, E., Srivastava, R., Rosen, B.R., Hyman, B.T., 1993. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J. Neurosci. 13, 4181-4192. (Pubitemid 23299942)
5. Beavo, J., 1995. Cyclic nucleotide phosphodiesterase: functional implications of multiple isoforms. Physiol. Rev. 75, 725-748.
6. Beene, D.L., Scott, J.D., 2008. A-kinase anchoring proteins take shape. Curr. Opin. Cell Biol. 19, 192-198. (Pubitemid 46394601)
7. Belmaker, R.H., Ebstein, R.P., Biederman, J., Stern, R., Berman, M., van Praag, H.M., 1978. The effect of L-DOPA and propranolol on human CSF cyclic nucleotides. Psychopharmacology (Berlin) 58, 307-310. (Pubitemid 8393433)
8. Bender, A.T., Beavo, J.A., 2006. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol. Rev. 58, 488-520. (Pubitemid 44394910)
9. Betarbet, R., Sherer, T.B., MacKenzie, G., Garcia-Osuna, M., Panov, A.V., Greenamyre, J.T., 2000. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 3, 1301-1306.
10. Biglan, K.M., Ross, C.A., Langbehn, D.R., Aylward, E.H., Stout, J.C., Queller, S., Carlozzi, N.E., Duff, K., Beglinger, L.J., Paulsen, J.S., 2009. Motor abnormalities in premanifest persons with Huntington's disease: the predict-HD study. Mov. Disord. 24, 1763-1772.
11. Billingsley, M.L., Polli, J.W., Balaban, C.D., Kincaid, R.L., 1990. Developmental expression of calmodulin-dependent cyclic nucleotide phosphodiesterase in rat brain. Brain Res. Dev. Brain Res. 53, 253-263. (Pubitemid 20161870)
12. Blum, D., Galas, M.C., Gall, D., Cuvelier, L., Schiffmann, S.N., 2002. Striatal and cortical neurochemical changes induced by chronic metabolic compromise in the 3-nitropropionic model of Huntington's disease. Neurobiol. Dis. 10, 410-426. (Pubitemid 35217592)
13. Bolger, G.B., Rodgers, L., Riggs, M., 1994. Differential CNS expression of alternative mRNA isoforms of the mammalian genes encoding cAMP-specific phospho-diesterases. Gene 149, 237-244. (Pubitemid 24361910)
14. Bollen, E., Prickaerts, J., 2012. Phosphodiesterases in neurodegenerative disorders. IUBMB Life 64, 965-970.
15. Borland, G., Smith, B.O., Yarwood, S.J., 2009b. EPAC proteins transducer diverse cellular actions of cAMP. Br. J. Pharmacol. 158, 70-86.
16. Braun, N.N., Reutiman, T.J., Lee, S., Folsom, T.D., Fatemi, S.H., 2007. Expression of phosphodiesterase 4 is altered in the brains of subjects with autism. NeuroReport 18, 1841-1844. (Pubitemid 350303763)
17. Brouillet, E., Jacquard, C., Bizat, N., Blum, D., 2005. 3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease. J. Neurochem. 95, 1521-1540. (Pubitemid 41804051)
18. Calabresi, P., Giacomini, P., Centonze, D., Bernardi, G., 2000b. Levodopa-induced dyskinesia: a pathological form of striatal synaptic plasticity? Annl. Neurol. 47, S60-S68.
19. Chauhan, N.B., Siegel, G.J., Lee, J.M., 2001. Depletion of glial cell line-derived neurotrophic factor in substantia nigra neurons of Parkinson's disease brain. J. Chem. Neuroanat. 21, 277-288. (Pubitemid 32592504)
20. Chen, R.W., Williams, A.J., Liao, Z., Yao, C., Tortella, F.C., Dave, J.R., 2007. Broad spectrum neuroprotection profile of phosphodiesterase inhibitors as related to modulation of cell-cycle elements and caspase-3 activation. Neurosci. Lett. 418, 165-169. (Pubitemid 46636000)
21. Chen, X., Xu, L., Radcliffe, P., Sun, B., Tank, A.W., 2008. Activation of tyrosine hydroxylase mRNA translation by cAMP in midbrain dopaminergic neurons. Mol. Pharmacol. 73, 1816-1828. (Pubitemid 351724369)
22. Cherry, J.A., Davis, R.L., 1999. Cyclic AMP phosphodiesterases are localized in regions of the mouse brain associated with reinforcement, movement, and affect. J. Comp. Neurol. 407, 287-301. (Pubitemid 29162777)
23. Cho, C.H., Cho, D.H., Seo, M.R., Juhnn, Y.S., 2000. Differential changes in the expression of cyclic nucleotide phosphodiesterase isoforms in rat brains by chronic treatment with electroconvulsive shock. Exp. Mol. Med. 32, 110-114.
24. Choi, Y.S., Lee, B., Cho, H.Y., Reyes, I.B., Pu, X.A., Saido, T.C., Hoyt, K.R., Obrietan, K., 2009. CREB is a key regulator of striatal vulnerability in chemical and genetic models of Huntington's disease. Neurobiol. Dis. 36, 259-268.
25. Cicchetti, F., Brownell, A.L., Williams, K., Chen, Y.I., Livni, E., Isacson, O., 2002. Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging. Eur. J. Neurosci. 15, 991-998. (Pubitemid 35463634)
26. Conti, M., Jin, S.L, 1999. The molecular biology of cyclic nucleotide phosphodiesterases. Prog. Nucleic Acid Res. Mol. Biol. 63, 1-38.
27. Coskran, T.M., Morton, D., Menniti, F.S., Adamowicz, W.O., Kleiman, R.J., Ryan, A.M., Strick, CA., Schmidt, C.J., Stephenson, D.T., 2006. Immunohistochemical localization of phosphodiesterase 10A in multiple mammalian species. J. Histochem. Cytochem. 54, 1205-1213. (Pubitemid 44623341)
28. Cramer, H., Warter, J.M., Renaud, B., 1984. Analysis of neurotransmitter metabolites and adenosine 3',5'-monophosphate in the CSF of patients with extrapyramidal motor disorders. Adv. Neurol. 40, 431-435.
29. Crocker, S.F., Costain, W.J., Robertson, H.A., 2006. DNA microarray analysis of striatal gene expression in symptomatic transgenic Huntington's mice (R6/2) reveals neuroinflammation and insulin associations. Brain Res. 1088, 176-186. (Pubitemid 43729411)
30. D'Sa, C, Eisch, A.J., Bolger, G.B., Duman, R.S., 2005. Differential expression and regulation of the cAMP-selective phosphodiesterase type 4A splice variants in rat brain by chronic antidepressant administration. Eur. J. Neurosci. 22, 1463-1475. (Pubitemid 41442418)
31. Dauer, W., Przedborski, S., 2003. Parkinson's disease: mechanisms and models. Neuron 39, 889-909. (Pubitemid 37130207)
32. Davis, G.C., Williams, A.C., Markey, S.P., 1979. Chronic parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res. 1, 249-254. (Pubitemid 10123385)
33. De la Monte, S.M., Vonsattel, J.P., Richardson Jr., E.P., 1988. Morphometric demonstration of atrophic changes in the cerebral cortex, white matter, and neostriatum in Huntington's disease. J. Neuropathol. Exp. Neurol. 47, 516-525.
34. De Rooij, J., Zwartkruis, F.J., Verheijen, M.H., Cool, R.H., Nijman, S.M., Wittinghofer, A., 1998. Epac is a Rap1 guaninenucleotide-exchange factor directly activated by cyclic AMP. Nature 396, 474-477. (Pubitemid 28553318)
35. Delghandi, M.P., Johannessen, M., Moens, U, 2005. The cAMP signalling pathway activates CREB through PKA, p38 and MSK1 in NIH 3T3 cells. Cell. Signalling 17, 1343-1351. (Pubitemid 41206644)
36. DeMarch, Z., Giampa, C, Patassini, S., Bernardi, G., Fusco, F.R., 2008. Beneficial effects of rolipram in the R6/2 mouse model of Huntington's disease. Neurobiol. Dis. 30, 375-387.
37. DeMarch, Z., Giampa, C, Patassini, S., Martorana, A., Bernardi, G., Fusco, F.R., 2007. Beneficial effects of rolipram in a quinolinic acid model of striatal excitotoxicity. Neurobiol. Dis. 25, 266-273. (Pubitemid 46127843)
38. Deshmukh, R., Sharma, V., Mehan, S., Sharma, N., Bedi, K.L, 2009. Amelioration of intracerebroventricular streptozotocin induced cognitive dysfunction and oxidative stress by vinpocetine - a PDE1 inhibitor. Eur. J. Pharmacol. 620, 49-56.
39. Desplats, P.A., Kass, K.E., Gilmartin, T., Stanwood, G.D., Woodward, E.L., Head, S.R., Sutcliffe, J.G., Thomas, E.A., 2006. Selective deficits in the expression of striatal-enriched mRNAs in Huntington's disease. J. Neurochem. 96, 743-757.
40. Devan, B.D., Bowker, J.L., Duffy, K.B., Bharati, I.S., Jimenez, M., Sierra-Mercado Jr., D., Nelson, CM., Spangler, E.L, Ingram, D.K., 2006. Phosphodiesterase inhibition by sildenafil citrate attenuates a maze learning impairment in rats induced by nitric oxide synthase inhibition. Psychopharmacology (Berlin) 183, 439-445. (Pubitemid 41721145)
41. Dlaboga, D., Hajjhussein, H., O'Donnell, J.M., 2008. Chronic haloperidol and clozapine produce different patterns of effects on phosphodiesterase-1B, -4B, and -10A expression in rat striatum. Neuropharmacology 54, 745-754.
42. Duff, K., Paulsen, J.S., Beglinger, L.J., Langbehn, D.R., Stout, J.C, 2007. Psychiatric symptoms in Huntington's disease before diagnosis: the predict-HD study. Biol. Psychiatry 62, 1341-1346. (Pubitemid 350180721)
43. Duff, K., Paulsen, J.S., Beglinger, L.J., Langbehn, D.R., Wang, C, Stout, J.C, Ross, C.A., Aylward, E., Carlozzi, N.E., Queller, S., 2010. "Frontal," behaviors before the diagnosis of Huntington's disease and their relationship to markers of disease progression: evidence of early lack of awareness. J. Neuropsychiatry Clin. Neurosci. 22, 196-207.
44. Emerich, D.F., Thanos, C.G., Goddard, M., Skinner, S.J., Geany, M.S., Bell, W.J., Bintz, B., Schneider, P., Chu, Y., Babu, R.S., Borlongan, C.V., Boekelheide, K., Hall, S., Bryant, B., Kordower, J.H., 2006. Extensive neuroprotection by choroid plexus transplants in excitotoxin lesioned monkeys. Neurobiol. Dis. 23, 471-480. (Pubitemid 44097036)
45. Erceg, S., Monfort, P., Hernandez-Viadel, M., Llansola, M., Montoliu, C, Felipo, V., 2005. Restoration of learning ability in hyperammonemic rats by increasing extracellular cGMP in brain. Brain Res. 1036, 115-121. (Pubitemid 40255850)
46. Fahn, S., Jankovic, J., 2007. Principles and Practice of Movement Disorders. Churchill Livingstone, Elsevier, Philadelphia, PA, pp. 1-652.
47. Feng, L., Wang, C.Y., Jiang, H., Oho, C, Mizuno, K., Dugich-Djordjevic, M., Lu, B., 1999. Differential effects of GDNF and BDNF on cultured ventral mesencephalic neurons. Brain Res. Mol. Brain Res. 66, 62-70. (Pubitemid 29148334)
48. Francis, S.H., Corbin, J.D., 1999. Cyclic nucleotide-dependent protein kinases: intracellular receptors for cAMP and cGMP action. Crit. Rev. Clin. Lab. Sci. 36, 275-328. (Pubitemid 29431414)
49. Fujishige, K., Kotera, J., Michibata, H., Yuasa, K., Takebayashi, S., Okumura, K., Omori, K., 1999. Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A). J. Biol. Chem. 274, 18438-18445.
50. Fujita, M., Imaizumi, M., D'Sa, C, Zoghbi, S.S., Crescenzo, M.S., Hong, J., Musachio, J.L, Gee, A.D., Seidel, J., Green, M.V., Pike, V.W, Duman, R.S., Innis, R.B., 2007. In vivo and in vitro measurement of brain phosphodiesterase 4 in rats after antidepressant administration. Synapse 61, 78-86. (Pubitemid 44927731)
51. Gallant, M., Aspiotis, R., Day, S., Dias, R., Dube, D., Dube, L., Friesen, R.W., Girard, M., Guay, D., Hamel, P., Huang, Z., Lacombe, P., Laliberte, S., Levesque, J.F., Liu, S., Macdonald, D., Mancini, J., Nicholson, D.W., Styhler, A., Townson, K., Waters, K., Young, R.N., Girard, Y, 2010. Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment. Bioorg. Med. Chem. Lett. 20, 6387-6393.
52. Garcia, M.J.A., Miriam, R., Sandra, A.G., Carmen, G., Concepcion, P., Ana, M., Santos, A., Perez-Castillo, A., 2011. Phosphodiesterase 7 inhibition preserves dopami-nergic neurons in cellular and rodent models of Parkinson disease. PLoS One 6, e17240.
53. Gekel, I., Neher, E., 2008. Application of an Epac activator enhances neurotransmitter release at excitatory central synapses. J. Neurosci. 28, 7991-8002.
54. Gelinas, J.N., Banko, J.L., Peters, M.M., Klann, E., Weeber, E.J., Nguyen, P.V., 2008. Activation of exchange protein activated by cyclic-AMP enhances long-lasting synaptic potentiation in the hippocampus. Learn. Mem. 15, 403-411. (Pubitemid 351786971)
55. Gerfen, C.R., Engber, T.M., Mathan, L.C., Susel, Z., Chase, T.N., Monsma, F.J., and Sibley., D. R., 1990. D1 and D2 dopamine receptor-regulated gene expression of striatoni-gral and striatopallidal neurons. Science 250, 1429-1432. (Pubitemid 120031867)
56. Giampa, C., Laurenti, D., Anzilotti, S., Bernardi, G., Menniti, F.S., Fusco, F.R., 2010. Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's disease. PLoS One 5, e13417.
57. Giampa, C., Middei, S., Patassini, S., Borreca, A., Marullo, F., Laurenti, D., Bernardi, G., Ammassari-Teule, M., Fusco, F.R., 2009. Phosphodiesterase type IV inhibition prevents sequestration of CREB binding protein, protects striatal parvalbumin interneurons and rescues motor deficits in the R6/2 mouse model of Huntington's disease. Eur. J. Neurosci. 29, 902-910.
58. Gil, J.M., Rego, A.C., 2008. Mechanisms of neurodegeneration in Huntington's disease. Eur. J. Neurosci. 27, 2803-2820. (Pubitemid 351832229)
59. Gines, S., Seong, I.S., Fossale, E., Ivanova, E., Trettel, F., Gusella, J.F., Wheeler, V.C., Persichetti, F., MacDonald, M.E., 2003. Specific progressive cAMP reduction implicates energy deficit in presymptomatic Huntington's disease knock-in mice. Hum. Mol. Gen. 12, 497-508. (Pubitemid 36312929)
60. Giorgi, M., D'Angelo, V., Esposito, Z., Nuccetelli, V., Sorge, R., Martorana, A., Stefani, A., Bernardi, G., Sancesario, G., 2008. Lowered cAMP and cGMP signalling in the brain during levedopa-induced dyskinesias in hemiParkinsonian rats: new aspects in the pathogenic mechanisms. Eur. J. Neurosci. 28, 941-950.
61. Giorgi, M., Melchiorri, G., Nuccetelli, V., D'Angelo, V., Martorana, A., Sorge, R., Castelli, V., Bernardi, G., Sancesario, G., 2011. PDE10A and PDE10A-dependent cAMP catabolism are dysregulated oppositely in striatum and nucleus accum-bens after lesion of midbrain dopamine neurons in rat: a key step in Parkinsonism physiopathology. Neurobiol. Dis. 43, 293-303.
62. Gloerich, M., Bos, J.L., 2010. Epac: defining a new mechanism for cAMP action. Annu. Rev. Pharmacol. Toxicol. 50, 355-375.
63. Gold, M.G., Lygren, B., Dokurno, P., Hoshi, N., McConnachie, G., Tasken, K., Carlson, C.R., Scott, J.D., Barford, D., 2006. Molecular basis of AKAP specificity for PKA regulatory subunits. Mol. Cell 24, 383-395. (Pubitemid 44647900)
64. Grandoch, M., Roscioni, S.S., Schmidt, M., 2010. The role of Epac proteins, novel cAMP mediators, in the regulation of immune, lung and neuronal function. Br. J. Pharmacol. 159, 265-284.
65. Greengard, P., 2001. The neurobiology of slow synaptic transmission. Science 294, 1024-1030. (Pubitemid 33041850)
66. Hakansson, K., Lindskog, M., Pozzi, L., Usiello, A., Fisone, G., 2004. DARPP-32 and modulation of cAMP signaling: involvement in motor control and levodopa-induced dyskinesia. Parkinsonism Rel. Disord. 10, 281-286. (Pubitemid 38757808)
67. Harvey, B.H., Bester, A., 2000. Withdrawal-associated changes in peripheral nitrogen oxides and striatal cyclic GMP after chronic haloperidol treatment. Behav. Brain Res. 111, 203-211. (Pubitemid 30326715)
68. Hebb, A.L.O., Robertson, H.A., Denovan-Wright, E.M., 2004. Striatal phosphodiester-ase mRNA and protein levels are reduced in Huntington's disease transgenic mice prior to the onset of motor symptoms. Neuroscience 123, 967-981. (Pubitemid 38130106)
69. Henn, V., Stefan, E., Baillie, G.S., Houslay, M.D., Rosenthal, W., Klussmann, E., 2005. Compartmentalized cAMP signalling regulates vasopressin mediated water reabsorption by controlling aquaporin-2. Biochem. Soc. Trans. 33, 1316-1318. (Pubitemid 41779676)
70. Hisahara, S., Shimohama, S., 2010. Toxin-induced and genetic animal models of Parkinson's disease. SAGE-Hindawi Access to Res. Parkinson's Dis., 1-14.
71. Howells, D.W., Porritt, M.J., Wong, J.Y., Batchelor, P.E., Kalnins, R., Hughes, A.J., Donnan, G.A., 2000. Reduced BDNF mRNA expression in the Parkinson's disease substantia nigra. Exp. Neurol. 166, 127-135.
72. Hulley, P., MHartikka, J., Abdel'Al, S., Engels, P., Buerki, H.R., Wiederhold, K.H., Muller, T., Kelly, P., Lowe, D., Lubbert, H., 1995. Inhibitors of type IV phospho-diesterases reduce the toxicity of MPTP in substantia nigra neurons in vivo. Eur. J. Neurosci. 7, 2431-2440.
73. Hung, H.C., Lee, E.H., 1996. The mesolimbic dopaminergic pathway is more resistant than the nigrostriatal dopaminergic pathway to MPTP and MPP+ toxicity: role of BDNF gene expression. Brain Res. Mol. Brain Res. 41, 14-26.
74. Hyman, C., Hofer, M., Barde, Y.A., Juhasz, M., Yancopoulos, G.D., Squinto, S.P., Lindsay, R.M., 1991. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature 350, 230-232. (Pubitemid 21912205)
75. Jenner, P., 2008. Molecular mechanisms of L-DOPA-induced dyskinesia. Nat. Rev. Neurosci. 9, 665-677.
76. Jiang, H., Nucifora Jr., F.C., Ross, C.A., DeFranco, D.B., 2003. Cell death triggered by polyglutamine-expanded huntingtin in a neuronal cell line is associated with degradation of CREB-binding protein. Hum. Mol. Gen. 12, 1-12. (Pubitemid 36097710)
77. Kaasinen, V., Ruottinen, H.M., Nagren, K., Lehikoinen, P., Oikonen, V., Rinne, J.O., 2000. Upregulation of putaminal dopamine D2 receptors in early Parkinson's disease: a comparative PET study with [11C] raclopride and [11C] N-Methyl-spiperone. J. Nucl. Med. 41, 65-70. (Pubitemid 30046685)
78. Kakkar, R., Raju, R.V.S., Rajput, A., Sharma, R.K., 1997. Amantadine: an anti Parkinsonian agent inhibits bovine 60 kDa calmodulin-dependent cyclic nucleotide phosphodiesterase isozyme. Brain Res. 749, 290-294. (Pubitemid 27104210)
79. Kakkar, R., Raju, R.V.S., Rajput, A., Sharma, R.K., 1996. Inhibition of bovine brain calmodulin-dependent cyclic nucleotide phosphodiesterase isozymes by deprenyl. Life Sci. 59, 337-341.
80. Kakkar, R., Raju, R.V.S., Sharma, R.K., 1999. Calmodulin-dependent cyclic nucleotide phosphodiesterase (PDE1). Cell. Mol. Life Sci. 55, 1164-1186. (Pubitemid 29361080)
81. Kim, W.G., Mohney, R.P., Wilson, B., Jeohn, G.H., Liu, B., Hong, J.S., 2000. Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia. J. Neurosci. 20, 6309-6316. (Pubitemid 30658427)
82. Kinderman, F.S., Kim, C., van Daake, S., Ma, Y., Pham, B.Q., Spraggon, G., Xuong, N.H., Jennings, P.A., Taylor, S.S., 2006. A dynamic mechanism for AKAP binding to RII isoforms of cAMP-dependent protein kinase. Mol. Cell 24, 397-408. (Pubitemid 44647908)
83. Kleiman, R.J., Kimmel, L.H., Bove, S.E., Lanz, T.A., Harms, J.F., Romegialli, A., Miller, K.S., Willis, A., des Etages, S., Kuhn, M., Schmidt, C.J., 2011. Chronic suppression of phosphodiesterase 10A alters striatal expression of genes responsible for neurotransmitter synthesis, neurotransmission, and signaling pathways implicated in Huntington' s disease. J. Pharmacol. Exp. Ther. 336, 64-76.
84. Kobayashi, T., Gamanuma, M., Sasaki, T., Yamashita, Y., Yuasa, K., Kotera, J., Omori, K., 2003. Molecular comparison of rat cyclic nucleotide phosphodiesterase 8 family: unique expression of PDE8B in rat brain. Gene 319, 21-31. (Pubitemid 37346197)
85. Kopperud, R., Krakstad, C., Selheim, F., Doskeland, S.O., 2003. cAMP effector mechanisms. Novel twists for an 'old' signaling system. FEBS Lett. 546, 121-126. (Pubitemid 36782292)
86. Krahe, T.E., Wang, W., Medina, A.E., 2009. Phosphodiesterase inhibition increases CREB phosphorylation and restores orientation selectivity in a model of fetal alcohol spectrum disorders. PLoS One 4, e6643.
87. Kruse, L.S., Moller, M., Kruuse, C., 2011. Distribution of PDE8A in the nervous system of the Sprague-Dawley rat. J. Chem. Neuroanat. 42, 184-191.
88. Kuhn, K., Wellen, J., Link, N., Maskri, L., Lubbert, H., Stichel, C.C., 2003. The mouse MPTP model: gene expression changes in dopaminergic neurons. Eur. J. Neurosci. 17, 1-12. (Pubitemid 36104204)
89. Kulkarni, S.K., Dhir, A., 2011. Animal models of tardive dyskinesia. Int. Rev. Neurobiol. 98, 265-287.
90. Kumer, S.C., Vrana, K.E., 1996. Intricate regulation of tyrosine hydroxylase activity and gene expression. J. Neurochem. 67, 443-462. (Pubitemid 26255637)
91. Laddha, S.S., Bhatnagar, S.P., 2009. A new therapeutic approach in Parkinson's disease: some novel quinazoline derivatives as dual selective phosphodiesterase 1 inhibitors and anti-inflammatory agents. Bioorg. Med. Chem. 17, 6796-6802.
92. Lakics, V., Karran, E.H., Boess, F.G., 2010. Quantitative comparison of phosphodies-terase mRNA distribution in human brain and peripheral tissues. Neurophar-macology 59, 367-374.
93. Lal, S., Sharma, R.K., McGregor, C., Macaulay, R.J., 1999. Immunohistochemical localization of calmodulin-dependent cyclic phosphodiesterase in the human brain. Neurochem. Res. 24, 43-49. (Pubitemid 29067775)
94. Langston, J.W., Ballard, P., Tetrud, J.W., Irwin, I., 1983. Chronic parkinsonism in humans due to a product of meperidine analog synthesis. Science 219, 979-980. (Pubitemid 13189531)
95. Langston, J.W., Forno, L.S., Tetrud, J., Reeves, A.G., Kaplan, J.A., Karluk, D., 1999. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Annal. Neurol. 46, 598-605. (Pubitemid 29466438)
96. Lesch, K.P., Lerer, B., 1991. The 5-HT receptor-G-protein-effector system complex in depression. I. Effect of glucocorticoids. J. Neural. Transm. Gen. Sect. 84, 3-18.
97. Levivier, M., Przedborski, S., Bencsics, C., Kang, U.J., 1995. Intrastriatal implantation of fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson's disease. J. Neurosci. 15, 7810-7820. (Pubitemid 26006890)
98. Lonze, B.E., Ginty, D.D., 2002. Function and regulation of CREB family transcription factors in the nervous system. Neuron 35, 605-623. (Pubitemid 35229980)
99. Lu, Y.F., Kandel, E.R., Hawkins, R.D., 1999. Nitric oxide signaling contributes to late-phase LTP and CREB phosphorylation in the hippocampus. J. Neurosci. 19, 10250-10261. (Pubitemid 30228032)
100. Luthi-Carter, R., Apostol, B.L., Dunah, A.W., DeJohn, M.M., Farrell, L.A., Bates, G.P., Young, A.B., Standaert, D.G., Thompson, L.M., Cha, J.H., 2004. Complex alteration of NMDA receptors in transgenic Huntington's disease mouse brain: analysis of mRNA and protein expression, plasma membrane association, interactingpro-teins, and phosphorylation. Neurobiol. Disord. 14, 624-636. (Pubitemid 37543539)
101. Luthi-Carter, R., Hanson, S.A., Strand, A.D., Bergstrom, D.A., Chun, W., Peters, N.L., Woods, A.M., Chan, E.Y., Kooperberg, C., Krainc, D., Young, A.B., Tapscott, S.J., Olson, J.M., 2002. Dysregulation of gene expressionin the R6/2 model of polyglutamine disease: parallel changes in muscle and brain. Hum. Mol. Gen. 15, 1911-1926.
102. Luthi-Carter, R., Strand, A., Peters, N.L., Solano, S.M., Hollingsworth, Z.R., 2000. Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum. Mol. Gen. 9, 1259-1271. (Pubitemid 30312475)
103. MacKenzie, S.J., Houslay, M.D., 2000. Action of rolipram on specific PDE4 cAMP phosphodiesterase isoforms and on the phosphorylation of cAMPresponse-element-binding protein (CREB) and p38 mitogen-activated protein (MAP) kinase in U937 monocytic cells. Biochem. J. 347, 571-578. (Pubitemid 30229406)
104. Majewski, H.K., Musgrave, I.F., 1995. Second messenger pathways in the modulation of neurotransmitter release. Aust. N.Z. J. Med. 25, 817-821. (Pubitemid 26022662)
105. Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S.W., Bates, G.P., 1996. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87, 493-506. (Pubitemid 26374323)
106. Martinez, M., Fernandez, E., Frank, A., Guaza, C., Fuente, M., Hernanz, A., 1999. Increased cerebrospinal fluid cAMP levels in Alzheimer's disease. Brain Res. 846, 265-267. (Pubitemid 29505164)
107. McCoy, M.K., Martinez, T.N., Ruhn, K.A., Szymkowski, D.E., Smith, C.G., Botterman, B. R., Tansey, K.E., Tansey, M.G., 2006. Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease. J. Neurosci. 26, 9365-9375. (Pubitemid 44396849)
108. McGeer, P.L., Schwab, C., Parent, A., Doudet, D., 2003. Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2, 3,6-tetrahydro-pyridine administration. Annl. Neurol. 54, 599-604. (Pubitemid 37346066)
109. McLachlan, C.S., Chen, M.L., Lynex, C.N., Goh, D.L., Brenner, S., Tay, S.K., 2007. Changes in PDE4D isoforms in the hippocampus of a patient with advanced Alzheimer disease. Arch. Neurol. 64, 456-457. (Pubitemid 46425708)
110. McLin, J.P., Thompson, L.M., Steward, O., 2006. Differential susceptibility to striatal neurodegeneration induced by quinolinic acid and kainate in inbred, outbred and hybrid mouse strains. Eur. J. Neurosci. 24, 3134-3140. (Pubitemid 44952645)
111. Menniti, F.S., Faraci, W.S., Schmidt, C.J., 2006. Phosphodiesterases in the CNS: targets for drug development. Nat. Rev. Drug Discovery 5, 660-670. (Pubitemid 44151604)
112. Merck and Co., 2006. MK0952 in patients with mild-to-moderate Alzheimer's disease. Available at (http://clinicaltrials.gov/show/NCT00362024).
113. Merz, K., Herold, S., Lie, D.C., 2011. CREB in adult neurogenesis - master and partner in the development of adult-born neurons? Eur. J. Neurosci. 33, 1078-1086.
114. Michele, P., Kellya, S., Loguea, F., Brennana, J., Jonathon, P.D., 2010. Phosphodiester-ase 11A in brain is enriched in ventral hippocampus and deletion causes psychiatric disease related phenotypes. PNAS 107, 8457-8462.
115. Miro, X., Perez-Torres, S., Palacios, J.M., Puigdomenech, P., Mengod, G., 2001. Differential distribution of cAMP-specific phosphodiesterase 7A mRNA in rat brain and peripheral organs. Synapse 40, 201-214. (Pubitemid 32322213)
116. Mogi, M., Togari, A., Kondo, T., Mizuno, Y., Komure, O., Kuno, S., Ichinose, H., Nagatsu, T., 1999. Brain-derived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson's disease. Neurosci. Lett. 270, 45-48. (Pubitemid 29322994)
117. Mohapel, P., Frielingsdorf, H., Haggblad, J., Zachrissonand, O., Brundin, P., 2005. Platelet-derived growth factor (PDGF-BB) and brain-derived neurotrophic factor (BDNF) induce striatal neurogenesis in adult rats with 6-hydroxydopamine lesions. Neuroscience 132, 767-776.
118. Murray, A.J., Shewan, D.A., 2008. Epac mediates cyclic AMP-dependent axon growth, guidance and regeneration. Mol. Cell Neurosci. 38, 578-588.
119. Neve, K.A., Seamans, J.K., Trantham-Davidson, H., 2004. Dopamine receptor signaling. J. Recept. Signal Transduction Res. 24, 165-205. (Pubitemid 39332216)
120. Nguyen, H.P., Metzger, S., Holzmann, C., Koczan, D., Thiesen, H.J., Von, H.S., Riess, O., Bonin, M., 2008. Age-dependent gene expression profile and protein expression in a transgenic rat model of Huntington's disease. Proteomics Clin. Appl. 2, 1638-1650.
121. Nishi, A., Kuroiwa, M., Miller, B.D., 2008. Distinct roles of PDE4 and PDE10A in the regulation of cAMP/PKA signaling in the striatum. J. Neurosci. 28, 10460-10471.
122. Nishino, N., Kitamura, N., Hashimoto, T., Tanaka, C., 1993. Transmembrane signalling systems in the brain of patients with Parkinson's disease. Rev. Neurosci. 4, 213-222. (Pubitemid 23223671)
123. Nucifora, F.C., Sasaki, M., Peters, M.F., Huang, H., Cooper, J.K., Yamada, M., Takahashi, H., Tsuji, S., Troncoso, J., Dawson, V.L., Dawson, T.M., Ross, C.A., 2001. Interference by huntingtin and atrophin-1 with CBP-mediated transcription leading to cellular toxicity. Science 291, 2423-2428. (Pubitemid 32231807)
124. Nunes, F., Ferreira-Rosa, K., Pereira, M., Kubruslyb, R.C., Manhaes, A.C., Abreu-Villac, Y., 2011. Acute administration of vinpocetine, a phosphodiesterase type 1 inhibitor, ameliorates hyperactivity in a mice model of fetal alcohol spectrum disorder. Drug Alcohol Depend. 119, 81-87.
125. Nuytemans, K., Theuns, J., Cruts, M., Broeckhoven, C.V., 2010. Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7 and LRRK2 genes. A mutation update. Hum. Mutat. 31, 763-780.
126. Olanow, C.W., Obeso, J.A., Stocchi, F., 2006. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol. 5, 677-687. (Pubitemid 44081890)
127. Oliveira, A.M., Abel, T., Brindle, P.K., Wood, M.A., 2006. Differential role for CBP and p300 CREB binding domain in motor skill learning. Behav. Neurosci. 120, 724-729. (Pubitemid 44050552)
128. Orr, C.F., Rowe, D.B., Mizuno, Y., Mori, H., Halliday, G.M., 2005. A possible role for humoral immunity in the pathogenesis of Parkinson's disease. Brain 128, 2665-2674. (Pubitemid 41552950)
129. Ouyang, M., Zhang, L., Zhu, J., Schwede, F., Thomas, S.A., 2008. Epac signaling is required for hippocampal dependent memory retrieval. Proc. Nat. Acad. Sci. U.S.A. 105, 11993-11997.
130. Pang, Z., Geddes, J.W., 1997. Mechanisms of cell death induced by the mitochondrial toxin 3-nitropropionic acid: acute excitotoxic necrosis and delayed apoptosis. J. Neurosci. 17, 3064-3073. (Pubitemid 27175819)
131. Parain, K., Murer, M.G., Yan, Q., Faucheux, B., Agid, Y., Hirsch, E., Raisman-Vozari, R., 1999. Reduced expression of brain-derived neurotrophic factor protein in Parkinson's disease substantia nigra. NeuroReport 10, 557-561. (Pubitemid 29333282)
132. Picconi, B., Bagetta, V., Ghiglieri, V., Paille, V., Filippo, M.D., Pendolino, V., Tozzi, A., Giampa, C., Fusco, F.R., Sgobio, C., Calabresi, P., 2011. Inhibition of phospho-diesterases rescues striatal long-term depression and reduces levodopa-induced dyskinesia. Brain 134, 375-387.
133. Picconi, B., Centonze, D., Hakansson, K., Bernardi, G., Greengard, P., Fisone, G., Cenci, M.A., Calabresi, P., 2003. Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat. Neurosci. 6, 501-506. (Pubitemid 36514698)
134. Polli, J.W., Kincaid, R.L., 1994. Expression of a calmodulin-dependent phosphodies-terase isoform (PDE1B1) correlates with brain regions having extensive dopaminergic innervation. J. Neurosci. 14, 1251-1261.
135. Porritt, M.J., Batchelor, P.E., Howells, D.W., 2005. Inhibiting BDNF expression by antisense oligonucleotide infusion causes loss of nigral dopaminergic neurons. Exp. Neurol. 192, 226-234. (Pubitemid 40208556)
136. Prickaerts, J., de Vente, J., Honig, W., Steinbusch, H.W., Blokland, A., 2002a. cGMP, but not cAMP, in rat hippocampus is involved in early stages of object memory consolidation. Eur. J. Pharmacol. 436, 83-87. (Pubitemid 34142401)
137. Prickaerts, J., Van Staveren, W.C.G., Sik, A., Markerink-van, I.M., Niewohnen, U., van der Staay, F.J., Blokland, A., de Vente, J., 2002b. Effects of two selective phosphodiesterase type 5 inhibitors, sildenafil and vardenafil, on object recognition memory and hippocampal cyclic GMP levels in the rat. Neuroscience 113, 351-361. (Pubitemid 34786180)
138. Prickaerts, J., Steinbusch, H.W., Smits, J.F., de Vente, J., 1997. Possible role of nitric oxide-cyclic GMP pathway in object recognition memory: effects of 7-nitroindazole and zaprinast. Eur. J. Pharmacol. 337, 125-136. (Pubitemid 27507775)
139. Puerta, E., Hervias, I., Goni-Allo, B., Lasheras, B., Jordan, J., Aguirre, N., 2009. Phosphodiesterase 5 inhibitors prevent 3,4- methylenedioxymethamphetami-neinduced 5-HT deficits in the rat. J. Neurochem. 108, 755-766.
140. Puerta, E., Hervias, I., Minones, L.B., Jordan, J., Ricobaraza, A., Tejedor, M.C., Garcia-Osta, A., Aguirre, N., 2010. Sildenafil protects against 3-nitropropionic acid neurotoxicity through the modulation of calpain, CREB, and BDNF. Neurobiol. Dis. 38, 237-245.
141. Puzzo, D., Staniszewski, A., Deng, S.X., Privitera, L., Leznik, E., Liu, S., Zhang, H., Feng, Y., Palmeri, A., Landry, D.W., Arancio, O., 2009. Phosphodiesterase 5 inhibition improves synaptic function, memory, and amyloid-beta load in an Alzheimer's disease mouse model. J. Neurosci. 29, 8075-8086.
142. Ramaswamy, S., McBride, J.L., Kordower, J.H., 2007. Animal models of Huntington's disease. ILAR J. 48, 356-373. (Pubitemid 350194368)
143. Ratra, M., Sharma, P.L., Gupta, R., 2011a. Neuroprotective effect of vinpocetine against 3-NP induced reduction of body weight and oxidative stress in rats. Int. J. Phytomed. 3, 362-369.
144. Ratra, M., Sharma, P.L., Gupta, R., 2011b. Evaluation of Vinpocetine on Locomotor Activity in 3-NP Induced Rats. Inventi Rapid: Molecular Pharmacology, Article ID-Inventi: pmp/119/11.
145. Reed, T.M., Browning, J.E., Blough, R.I., Vorhees, C.V., Repaske, D.R., 1998. Genomic structure and chromosome location of the murine PDE1B phosphodiesterase gene. Mamm. Genome 9, 571-576. (Pubitemid 28323769)
146. Reinhardt, R.R., Chin, E., Zhou, J., Taira, M., Murata, T., Manganiello, V.C., Bondy, C.A., 1995. Distinctive anatomical patterns of gene expression for cGMP-inhibited cyclic nucleotide phosphodiesterases. J. Clin. Invest. 95, 1528-1538.
147. Repaske, D.R., Corbin, J.G., Conti, M., Goy, M.F., 1993. A cyclic GMP stimulated cyclic nucleotide phosphodiesterase gene is highly expressed in the limbic system of the rat brain. Neuroscience 56, 673-686. (Pubitemid 23290579)
148. Reyes, I.E., Markerink-Van, I.M., Mengod, G., De, V.J., 2007. Expression of the cGMP-specific phosphodiesterases 2 and 9 in normal and Alzheimer's disease human brains. Eur. J. Neurosci. 25, 3332-3338. (Pubitemid 46872773)
149. Ribeiro, C.A., Grando, V., Dutra Filho, C.S., Wannmacher, C.M., Wajner, M., 2006. Evidence that quinolinic acid severely impairs energy metabolism through activation of NMDA receptors in striatum from developing rats. J. Neurochem. 99, 1531-1542. (Pubitemid 44924231)
150. Richter, W., Jin, S.L., Conti, M., 2005. Splice variants of the cyclic nucleotide phosphodiesterase PDE4D are differentially expressed and regulated in rat tissue. Biochem. J. 388, 803-811. (Pubitemid 40941566)
151. Roberts, R.C., Gaither, L.A., Gao, X.M., Kashyap, S.M., Tamminga, C.A., 1995. Ultrastructural correlates of haloperidol-induced oral dyskinesias in rat stria-tum. Synapse 20, 234-243.
152. Rutten, K., Prickaerts, J., Blokland, A., 2006. Rolipram reverses scopolamine-induced and time dependent memory deficits in object recognition by different mechanisms of action. Neurobiol. Learn. Mem. 85, 132-138. (Pubitemid 43247839)
153. Rutten, K., Prickaerts, J., Hendrix, M., van der Staay, F.J., Sik, A., Blokland, A., 2007. Time-dependent involvement of cAMP and cGMP in consolidation of object memory: studies using selective phosphodiesterase type 2, 4 and 5 inhibitors. Eur. J. Pharmacol. 558, 107-112. (Pubitemid 46328881)
154. Rutten, K., Vente, J.D., Sik, A., Ittersum, M.M., Prickaerts, J., Blokland, A., 2005. The selective PDE5 inhibitor, sildenafil, improves object memory in Swiss mice and increases cGMP levels in hippocampal slices. Behav. Brain Res. 164, 11-16. (Pubitemid 41253727)
155. Sabban, E.L., Kvetnansky, R., 2001. Stress-triggered activation of gene expression in catecholaminergic systems: dynamics of transcriptional events. Trends Neurosci. 24, 91-98. (Pubitemid 32115439)
156. Samii, A., Nutt, J.G., Ransom, B.R., 2004. Parkinson's disease. Lancet 363, 1783-1793. (Pubitemid 38698383)
157. Sancesario, G., Giorgi, M., D'Angelo, V., Modica, A., Martorana, A., Morello, M., Bengtson, C.P., Bernardi, G., 2004. Down-regulation of nitrergic transmission in the rat striatum after chronic nigrostriatal deafferentation. Eur. J. Neurosci. 20, 989-1000. (Pubitemid 39141305)
158. Sasaki, H., Hashimoto, K., Inada, T., Fukui, S., Iyo, M., 1995. Suppression of oro-facial movements by rolipram, a cAMP phosphodiesterase inhibitor, in rats chronically treated with haloperidol. Eur. J. Pharmacol. 282, 71-76.
159. Sasaki, T., Kotera, J., Omori, K., 2002. Novel alternative splice variants of rat phosphodiesterase 7B showing unique tissue-specific expression and phos-phorylation. Biochem. J. 361, 211-220. (Pubitemid 34174488)
160. Sasaki, T., Kitagawa, K., Omura-Matsuoka, E., Todo, K., Terasaki, Y., Sugiura, S., Hatazawa, J., Yagita, Y., Hori, M., 2007. The phosphodiesterase inhibitor rolipram promotes survival of newborn hippocampal neurons after ischemia. Stroke 38, 1597-1605. (Pubitemid 46684180)
161. Schilling, G., Becher, M.W., Sharp, A.H., Jinnah, H.A., Duan, K., Kotzuk, J.A., and Slunt., H. H., Ratovitski, T., Cooper, J.K., Jenkins, N.A., Copeland, N.G., Price, D.L., Ross, C.A., Borchelt, D.R., 1999. Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum. Mol. Genet. 8, 397-407. (Pubitemid 29097327)
162. Schwarting, R.K.W., Huston, J.P., 1996. Unilateral 6-hydroxydopamine lesions of meso-striatal dopamine neurons and their physiological sequelae. Prog. Neu-robiol. 49, 215-266. (Pubitemid 26276331)
163. Schwarting, R.K.W., Huston, J.P., 1997. Behavioral and neurochemical dynamics of neurotoxic meso-striatal dopamine lesions. Neurotoxicology 18, 689-708. (Pubitemid 27430298)
164. Seeger, T.F., Bartlett, B., Coskran, T.M., Culp, J.S., James, L.C., Krull, D.L., Lanfear, J., Ryan, A.M., Schmidt, C.J., Strick, C.A., Varghese, A.H., Williams, R.D., Wylie, P.G., Menniti, F.S., 2003. Immunohistochemical localization of PDE10A in the rat brain. Brain Res. 985, 113-126. (Pubitemid 37088176)
165. Sharma, V., Bala, A., Deshmukh, R., Bedi, K.L., Sharma, P.L., 2012. Neuroprotective effect of RO-20-1724 - a phosphodiesterase4 inhibitor against intracerebroven-tricular streptozotocin induced cognitive deficit and oxidative stress in rats. Pharmacol. Biochem. Behav. 101, 239-245.
166. Shults, C.W., Kimber, T., Altar, C.A., 1995. BDNF attenuates the effects of intrastriatal injection of 6-hydroxydopamine. NeuroReport 6, 1109-1112.
167. Siderowf, A., Stern, M., 2003. Update on Parkinson disease. Ann. Intern. Med. 138, 651-658. (Pubitemid 38124657)
168. Simola, N., Morelli, M., Carta, A.R., 2007. The 6-hydroxydopamine model of Parkinson's disease. Neurotox Res. 11 (3-4), 151-167.
169. Smith, S.M., Uslaner, J.M., Cox, C.D., Huszar, S.L., Cannon, C.E., 2012. The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey. Neuropharmacology 64, 215-223.
170. Staveren, V.W.C., Steinbusch, H.W., Markerink-Van Ittersum, M., Repaske, D.R., Goy, M.F., Kotera, J., Omori, K., Beavo, J.A., De Vente, J., 2003. mRNA expression patterns of the cGMP hydrolyzing phosphodiesterases types 2, 5, and 9 during development of the rat brain. J. Comp. Neurol. 467, 566-580. (Pubitemid 37467131)
171. Staveren, V.W.C., Steinbusch, H.W., Markerink-van, I.M., Behrends, S., de Vente, J., 2004. Species differences in the localization of cGMP producing and NO-responsive elements in the mouse and rat hippocampus using cGMP immu-nocytochemistry. Eur. J. Neurosci. 19, 2155-2168. (Pubitemid 38582204)
172. Steffan, J.S., Bodai, L., Pallos, J., Poelman, M., McCampbell, A., 2001. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 413, 739-743. (Pubitemid 33009952)
173. Steffan, J.S., Kazantsev, A., Spasic-Boskovic, O., Greenwald, M., Zhu, Y.Z., 2000. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc. Nat. Acad. Sci. U.S.A. 97, 6763-6768. (Pubitemid 30412788)
174. Sun, M.L., Kong, X., Wang, X., Lu, Q., Gao, Geller, A.I., 2005. Comparison of the capability of GDNF, BDNF, or both, to protect nigrostriatal neurons in a rat model of Parkinson's disease. Brain Res. 1052, 119-129. (Pubitemid 41116769)
175. Taylor, S.S., Kim, C., Cheng, C.Y., Brown, S.H.J., Wu, J., Kannan, N., 2008. Signaling through cAMP and cAMP-dependent protein kinase: diverse strategies for drug design. Biochim. Biophys. Acta 1784, 16-26.
176. Torres, P.S., Cortes, R., Tolnay, M., Probst, A., Palacios, J.M., Mengod, G., 2003. Alterations on phosphodiesterase type 7 and 8 isozyme mRNA expression in Alzheimer's disease brains examined by in situ hybridization. Exp. Neurol. 182, 322-334. (Pubitemid 36937085)
177. Vaandrager, A.B., de Jonge, H.R., 1996. Signalling by cGMP-dependent protein kinases. Mol. Cell Biochem. 157, 23-30. (Pubitemid 26142433)
178. van der Staay, F.J., Rutten, K., Bärfacker, L., DeVry, J., Erb, C., Heckroth, H., Karthaus, D., Tersteegen, A., van Kampen, M., Blokland, A., Prickaerts, J., Reymann, K.G., Schröder, U.H., Hendrix, M., 2008. The novel selective PDE9 inhibitor BAY 73-6691 improves learning and memory in rodents. Neuropharmacology, 55, 908-918.
179. Volicer, L., Beal, M.F., Direnfeld, L.K., Marquis, J.K., Albert, M.L., 1986. CSF cyclic nucleotides and somatostatin in Parkinson's disease. Neurology 36, 89-92. (Pubitemid 16186057)
180. Vonsattel, J.P., Myers, R.H., Stevens, T.J., Ferrante, R.J., Bird, E.D., Richardson Jr., E.P., 1985. Neuropathological classification of Huntington's disease. J. Neuropathol. Exp. Neurol. 44, 559-577. (Pubitemid 16196286)
181. Wakabayashi, K., Tanji, K., Mori, F., Takahashi, H., 2007. The Lewy body in Parkinson's disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates. Neuropathology 27, 494-506. (Pubitemid 47459715)
182. Wakabayashi, K., Tanji, K., Odagiri, S., Miki, Y., Mori, F., Takahashi, H., 2013. The lewy body in Parkinson's disease and related neurodegenerative disorders. Mol. Neurobiol. 47, 495-508.
183. Walker, F.O., 2007. Huntington's disease. Lancet 369, 218-228. (Pubitemid 46107685)
184. Watanabe, T., Zhang, N., Liu, M., Tanaka, R., Mizuno, Y., Urabe, T., 2006. Cilostazol protects against brain white matter damage and cognitive impairment in a rat model of chronic cerebral hypoperfusion. Stroke 37, 1539-1545. (Pubitemid 44305739)
185. West, A.R., Grace, A.A., 2000. Striatal nitric oxide signaling regulates the neuronal activity of midbrain dopamine neurons in vivo. J. Neurophysiol. 83, 1796-1808. (Pubitemid 30198637)
186. Wong, W., Scott, J.D., 2004. AKAP signalling complexes: focal points in space and time. Nat. Rev. Mol. Cell Biol. 5, 959-970. (Pubitemid 39611533)
187. Xie, Z., Adamowicz, W.O., Eldred, W.D., Jakowski, A.B., Kleiman, R.J., Morton, D.G., Stephenson, D.T., Strick, C.A., Williams, R.D., Menniti, F.S., 2006. Cellular and subcellular localization of PDE10A, a striatum-enriched phosphodiesterase. Neuroscience 139, 597-607.
188. Yamashita, N., Miyashiro, M., Baba, J., Sawa, A., 1997a. Rolipram, a selective inhibitor of phosphodiesterase type 4, pronouncedly enhanced the forskolin-induced promotion of dopamine biosynthesis in primary cultured rat mesencephalic neurons. Jpn. J. Pharmacol. 75, 91-95. (Pubitemid 27462579)
189. Yamashita, N., Hayashi, A., Baba, J., Sawa, A., 1997b. Rolipram, a phosphodiesterase-4-selective inhibitor, promotes the survival of cultured rat dopaminergic neurons. Jpn. J. Pharmacol. 75, 155-159. (Pubitemid 27491550)
190. Yan, C., Bentley, J.K., Sonnenburg, W.K., Beavo, J.A., 1994. Differential expression of the 61 kDa and 63 kDa calmodulin-dependent phosphodiesterases in the mouse brain. J. Neurosci. 14, 973-984. (Pubitemid 24081897)
191. Yan, C., Zhao, A.Z., Bentley, J.K., Beavo, J.A., 1996. The calmodulin dependent phosphodiesterase gene PDE1C encodes several functionally different splice variants in a tissue-specific manner. J. Biol. Chem. 271, 25699-25706. (Pubitemid 26337952)
192. Yang, L., Calingasan, N.Y., 2008. Attenuation of MPTP neurotoxicity by rolipram, a specific inhibitor of phosphodiesterase IV. Exp. Neurol. 211, 311-314.
193. Yero Tatiana, Rey, Jose A., 2008. Tetrabenazine (Xenazine), An FDA-approved treatment option for huntington's disease - related chorea. Pharmacy and Therapeutics. 33(12); 690-694.
194. Zachary, C., Baquet, P.C.B., Kevin, R.J., 2005. Brain-derived neurotrophic factor is required for the establishment of the proper number of dopaminergic neurons in the substantia nigra pars compacta. J. Neurosci. 25, 6251-6259.
195. Zaitone, S.A., Elmatty, D.M.A., Elshazly, S.M., 2012. Piracetam and vinpocetine ameliorate rotenone-induced Parkinsonism in rats. Indian J. Pharmacol. 44, 774-779.
196. Zhang, H.T., O'Donnell, J.M., 2000. Effects of rolipram on scopolamine induced impairment of working and reference memory in the radial-arm maze tests in rats. Psychopharmacology (Berlin) 150, 311-316. (Pubitemid 30447851)
197. Zhang, L., Zhang, Z., Zhang, R.L., Cui, Y., La Pointe, M.C., Silver, B., Chopp, M., 2006a. Tadalafil, a long-acting type 5 phosphodiesterase isoenzyme inhibitor, improves neurological functional recovery in a rat model of embolic stroke. Brain Res. 1118, 192-198. (Pubitemid 44633866)
198. Zhang, R.L., Zhang, Z., Zhang, L., Wang, Y., Zhang, C., Chopp, M., 2006b. Delayed treatment with sildenafil enhances neurogenesis and improves functional recovery in aged rats after focal cerebral ischemia. J. Neurosci. Res. 83, 1213-1219. (Pubitemid 43668004)
199. Zuccato, C., Ciammola, A., Rigamonti, D., Leavitt, B.R., Goffredo, D., Conti, L., MacDonald, M.E., Friedlander, R.M., Silani, V., Hayden, M.R., Timmusk, T., Sipione, S., Cattaneo, E., 2001. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 293, 493-498. (Pubitemid 32679077)
200. Zuccato, C., Cattaneo, E., 2009. Brain-derived neurotrophic factor in neurodegen-erative diseases. Nat. Rev. Neurol. 5, 311-322.
201. Zuccato, C., Valenza, M., Cattaneo, E., 2010. Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol. Rev. 90, 905-981.